Talk:Basaloid squamous cell lung carcinoma

Comments
asked me to review. It looks quite comprehensive and understandable. My first (and main) question is why this aspect cannot be covered in context in the squamous cell lung carcinoma section on NSCLC.
 * I would recommend templating the references with cite journal and adding PMID, DOI and PMC codes as available - this makes it easier to access the references online.
 * Some references are primary sources, and should ideally be replaced with MEDRS-compatible reviews if available.
 * I have taken the liberty of moving "Discovery" down to "History" (as recommended in WP:MEDMOS)

In general very good work! JFW &#124; T@lk  10:57, 26 June 2011 (UTC)

Response to Dr. Wolff
First of all, THANKS for taking a look. And your kind words! Appreciate it :-) And as a sop, I'm trying to do the PMID/diberri thing as we speak ... yuk.

All that said ... Doc, your BLASPHEMY!!! Subsuming this variant within SqCC within NSCLC??? Oh, the SHAME! Egad! I see now, sir, that you're a "lumper", and therefore, probably still a fan of the diagnosis "NSCLC NOS" (not to mention cooking over a wood fire started with flint and steel)! LOL!

As I'm SURE you know ... we are FINALLY beginning to hit at NSCLC according to histotype (a/k/a the cheap, readily available, correlative proxy for molecular status). EGFR mutants correlate with nonmucinous BAC and papillary AdC variants, K-ras mutants to mucinous and mixed BAC, EML4-ALK/crizotinib in signet ring cell types, etc. Other stuff comes to mind too, like cisplatin + gemcitabine seems better in SqCC vs. other doublets, off the top of my head. Less well known ones I can think of (after only one cup of coffee) include EBV-driven targets in LELC, CK8 mutations in rhabdoid variants, one particular receptor mutation (drawing a temporary blank) in giant cell variants, glycolysis-directed or biotin-directed modulators in clear cell variants. There's some "no-no" issues out there too - antiangiogenesis in certain SqCC (bulky, central, with big vessels).

Lastly, you ARE going to see treatment regimens selected for various histotypes based on multivariant analyses of stuff already tried, compiled from published case series in the lit ... and not just primary site-specific tumors either, but MORPHOLOGY BASED across tissue types! We are already seeing this with LELC and some of the salivary-gland like carcinomas!

Within the next decade, the variants are going to ALL pretty much be treated individually. I say "splitting", not "lumping"! What say ye and your compadres? :-)~

Your fan: Cliff Knickerbocker, M.S. (&#91;&#91;User talk:Uploadvirus&#124;talk&#93;&#93;) (talk) 12:01, 26 June 2011 (UTC)


 * I'm often a cautious lumper until I can be persuaded to become a splitter. Better to have the major stuff in context, you see? But I will happily split along if there is such as strong case for giving this topic a separate treatment. JFW &#124; T@lk  13:11, 26 June 2011 (UTC)